Heat Biologics Inc (HTBX) Downgraded by Zacks Investment Research to Hold
Heat Biologics Inc (NASDAQ:HTBX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Saturday.
According to Zacks, “Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company’s products under development include HS-110 for the treatment of non-small cell lung cancer, HS-410 for the bladder cancer treatment, HS-310 to treat ovarian cancer and HS-510 for treating triple negative breast cancer. Heat Biologics, Inc. is based in Chapel Hill, North Carolina. “
Separately, Noble Financial restated a “buy” rating on shares of Heat Biologics in a research note on Sunday, May 14th.
Shares of Heat Biologics (NASDAQ:HTBX) opened at 0.67 on Friday. The company’s market cap is $23.86 million. Heat Biologics has a 52-week low of $0.57 and a 52-week high of $3.35. The stock’s 50 day moving average price is $0.72 and its 200-day moving average price is $0.93.
Heat Biologics (NASDAQ:HTBX) last issued its quarterly earnings results on Friday, March 31st. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by $0.05. The business had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.13 million. Equities analysts expect that Heat Biologics will post ($0.63) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Heat Biologics Inc (HTBX) Downgraded by Zacks Investment Research to Hold” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/10/heat-biologics-inc-htbx-downgraded-by-zacks-investment-research-to-hold-2.html.
Hedge funds have recently modified their holdings of the stock. KCG Holdings Inc. increased its stake in shares of Heat Biologics by 35.3% in the first quarter. KCG Holdings Inc. now owns 175,769 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 45,831 shares in the last quarter. Oxford Asset Management purchased a new stake in shares of Heat Biologics during the fourth quarter valued at approximately $274,000. Vanguard Group Inc. increased its stake in shares of Heat Biologics by 132.4% in the first quarter. Vanguard Group Inc. now owns 591,098 shares of the biopharmaceutical company’s stock valued at $526,000 after buying an additional 336,744 shares in the last quarter. Finally, Sabby Management LLC purchased a new stake in shares of Heat Biologics during the first quarter valued at approximately $2,176,000. Institutional investors own 1.78% of the company’s stock.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.